摘要
目的观察丹七软胶囊联合曲美他嗪治疗冠心病心绞痛的临床效果。方法选择2017年3月—2019年5月江苏省苏北人民医院收治的104例冠心病心绞痛患者,按照随机数字表法将其分为对照组和观察组,各52例。对照组采用曲美他嗪治疗,观察组在对照组的基础上加用丹七软胶囊治疗,两组均持续治疗4周。治疗后进行临床疗效评价。比较两组心绞痛的视觉模拟评分(VAS)、持续时间、发作次数及乳酸脱氢酶(LDH)、谷草转氨酶(AST)、肌酸激酶同工酶(CK-MB)、一氧化氮(NO)、内皮素-1(ET-1)、纤维蛋白原(FIB)、凝血酶原时间(PT)水平。比较两组治疗过程中的不良反应。结果观察组临床总有效率高于对照组(P<0.05)。治疗后,两组VAS较治疗前降低,持续时间较治疗前缩短,发作次数较治疗前减少,且观察组治疗后VAS低于对照组,持续时间短于对照组,发作次数少于对照组,差异均有统计学意义(P<0.05)。治疗后两组LDH、AST、CK-MB、ET-1和FIB水平较治疗前均降低(P<0.05),且观察组治疗后LDH、AST、CK-MB、ET-1和FIB水平均低于对照组(P<0.05)。治疗后两组NO、PT水平均显著高于治疗前(P<0.05),且观察组治疗后NO、PT水平均高于对照组(P<0.05)。两组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论丹七软胶囊联合曲美他嗪治疗冠心病心绞痛可明显缓解心绞痛疼痛程度,缩短疼痛持续时间,减少发作次数,降低LDH、AST、CK-MB、ET-1和FIB水平,升高NO、PT水平,临床疗效较好,且无明显不良反应。
Objective To observe the clinical effect of Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary artery heart disease.Methods One hundred and four patients with angina pectoris of coronary heart disease admitted to Northern Jiangsu People’s Hospital from March 2017 to May 2019 were selected and divided into control group and observation group by random number table method,with 52 cases in each group.The control group was treated with Trimetazidine,while the observation group was treated with Danqi Soft Capsules on the basis of control group.Both groups were treated for 4 weeks.The clinical efficacy was evaluated after treatment.The visual analogue scale(VAS)of angina pectoris,duration and attack times of angina pectoris,lactic acid dehydrogenase(LDH),aspartate aminotransferase(AST),creatine kinase isoenzyme(CK-MB),nitric oxide(NO),endothelin-1(ET-1),fibrinogen(FIB)and prothrombin time(PT)were compared between the two groups.The adverse reactions during treatment were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group(P<0.05).After treatment,VAS in the two groups was lower than that before treatment,the duration was shorter than that before treatment,and the attack times of angina pectoris were less than that before treatment.Moreover,VAS in the observation group was lower than that in the control group,the duration was shorter than that in the control group,and the attack times were less than that in the control group,and the differences were statistically significant(P<0.05).After treatment,the LDH,AST,CK-MB,ET-1 and FIB levels in the two groups were lower than those before treatment(P<0.05),and the LDH,AST,CK-MB,ET-1 and FIB levels in the observation group were lower than those in the control group(P<0.05).The NO and PT levels in the two groups were significantly higher than those before treatment(P<0.05),and NO and PT levels in the observation group were higher than those in the control
作者
费燕
潘俊
FEI Yan;PAN Jun(Department of Pharmacy,Northern Jiangsu People’s Hospital,Jiangsu Province,Yangzhou225001,China)
出处
《中国医药导报》
CAS
2020年第35期148-151,155,共5页
China Medical Herald
基金
江苏省医学科研基金项目(M2016030)。
关键词
丹七软胶囊
曲美他嗪
冠心病
心绞痛
Danqi Soft Capsules
Trimetazidine
Coronary heart disease
Angina pectoris
